Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down - Here's Why

Key Points

• Genmab A/S shares gapped down significantly, opening at $304.70 after a previous close of $332.00, reflecting an 8.2% drop.
• The company reported quarterly earnings of $5.42 per share, exceeding analysts' expectations of $3.99, although revenue of $925 million fell short of estimates of $949.06 million.
• Genmab A/S, known for developing antibody therapeutics for various cancers, has a market capitalization of $20.13 billion and a price-to-earnings ratio of 15.30.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s stock price gapped down before the market opened on Monday . The stock had previously closed at $332.00, but opened at $304.70. Genmab A/S shares last traded at $304.70, with a volume of 17,401 shares.

Genmab A/S Stock Down 8.2%

The stock has a 50 day moving average of $277.77 and a 200 day moving average of $231.76. The company has a market capitalization of $20.13 billion, a price-to-earnings ratio of 15.30 and a beta of 0.95.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $5.42 EPS for the quarter, topping analysts' consensus estimates of $3.99 by $1.43. The company had revenue of $925.00 million for the quarter, compared to analyst estimates of $949.06 million. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.